Transcenta Holding
创胜集团
Executive Summary
Transcenta is a dual-listed (HK/HKEX: 6628) Chinese biotech with operations in Shanghai and Princeton, focusing on innovative biologics and oncology therapeutics. The company maintains clear BIOSECURE status and has demonstrated active deal-making capabilities with international partnerships. Strong pipeline in oncology and immunology with multiple assets in clinical development makes it an attractive BD target for US pharma seeking China exposure without regulatory complications.
Structure: Transcenta operates as a Hong Kong-listed holding company with dual headquarters in Shanghai and Princeton, suggesting a structure designed for international operations and partnerships. The Princeton presence indicates established US operations infrastructure, which should facilitate due diligence and partnership execution for US-based deals.
Ownership & Shareholder Structure
Transcenta Holding → AstraZeneca
Transcenta bispecific antibody collaboration with AstraZeneca.
BIOSECURE Risk
Company maintains clear BIOSECURE status with no BCC designation and dual Shanghai/Princeton operations suggesting international compliance focus
Key Exposures:
- •Standard Chinese biotech regulatory exposure
- •Potential supply chain dependencies in China
Mitigation: Princeton operations provide US operational footprint; clear BIOSECURE status indicates proactive compliance management
BD Intelligence
Therapeutic Areas:
Recent Deals: Limited visibility on recent out-licensing activity - requires further investigation during BD discussions
Approach: Direct approach through Princeton office for US partnerships; leverage Hong Kong listing as indicator of international standards and transparency
Red Flags
- ⚠Limited public disclosure on management team and corporate governance
- ⚠Insufficient visibility into recent partnership activity and deal execution capability
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.